Summary

Oncology Nutrition Market – Scope of Report
TMR’s report on the global oncology nutrition market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global oncology nutrition market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oncology nutrition market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the oncology nutrition market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oncology nutrition market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oncology nutrition market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oncology nutrition market.

The report delves into the competitive landscape of the global oncology nutrition market. Key players operating in the global oncology nutrition market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oncology nutrition market profiled in this report.

Key Questions Answered in Global oncology nutrition Market Report
• What is the sales/revenue generated by oncology nutrition across all regions during the forecast period?
• What are the opportunities in the global oncology nutrition market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Oncology Nutrition Market – Research Objectives and Research Approach
The comprehensive report on the global oncology nutrition market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oncology nutrition market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oncology nutrition market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncology Nutrition Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncology Nutrition Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Oncology Nutrition Market Analysis and Forecast, by Cancer Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cancer Type, 2017–2031
6.3.1. Head and Neck Cancer
6.3.2. Colorectal Cancer
6.3.3. Hematology Cancer
6.3.4. Prostate Cancer
6.3.5. Breast Cancer
6.3.6. Gastrointestinal Cancer
6.3.7. Lung Cancer
6.3.8. Pancreatic Cancer
6.3.9. Others
6.4. Market Attractiveness, by Cancer Type
7. Global Oncology Nutrition Market Analysis and Forecast, by Nutrition
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Nutrition, 2017–2031
7.3.1. Enteral Nutrition
7.3.2. Parenteral Nutrition
7.4. Market Attractiveness, by Nutrition
8. Global Oncology Nutrition Market Analysis and Forecast, by Formula
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Formula, 2017–2031
8.3.1. Standard Formula
8.3.2. Elemental Formula
8.3.3. Specialized Formula
8.4. Market Attractiveness, by Formula
9. Global Oncology Nutrition Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Inpatient Nutrition
9.3.2. Outpatient Nutrition
9.4. Market Attractiveness, by Distribution Channel
10. Global Oncology Nutrition Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Oncology Nutrition Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Cancer Type, 2017–2031
11.2.1. Head and Neck Cancer
11.2.2. Colorectal Cancer
11.2.3. Hematology Cancer
11.2.4. Prostate Cancer
11.2.5. Breast Cancer
11.2.6. Gastrointestinal Cancer
11.2.7. Lung Cancer
11.2.8. Pancreatic Cancer
11.2.9. Others
11.3. Market Attractiveness, by Cancer Type
11.4. Market Value Forecast, by Nutrition, 2017–2031
11.4.1. Enteral Nutrition
11.4.2. Parenteral Nutrition
11.5. Market Attractiveness, by Nutrition
11.6. Market Value Forecast, by Formula, 2017–2031
11.6.1. Standard Formula
11.6.2. Elemental Formula
11.6.3. Specialized Formula
11.7. Market Attractiveness, by Formula
11.8. Market Value Forecast, by Distribution Channel
11.8.1. Inpatient Nutrition
11.8.2. Outpatient Nutrition
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Cancer Type
11.11.2. By Nutrition
11.11.3. By Formula
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Oncology Nutrition Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Cancer Type, 2017–2031
12.2.1. Head and Neck Cancer
12.2.2. Colorectal Cancer
12.2.3. Hematology Cancer
12.2.4. Prostate Cancer
12.2.5. Breast Cancer
12.2.6. Gastrointestinal Cancer
12.2.7. Lung Cancer
12.2.8. Pancreatic Cancer
12.2.9. Others
12.3. Market Attractiveness, by Cancer Type
12.4. Market Value Forecast, by Nutrition, 2017–2031
12.4.1. Enteral Nutrition
12.4.2. Parenteral Nutrition
12.5. Market Attractiveness, by Nutrition
12.6. Market Value Forecast, by Formula, 2017–2031
12.6.1. Standard Formula
12.6.2. Elemental Formula
12.6.3. Specialized Formula
12.7. Market Attractiveness, by Formula
12.8. Market Value Forecast, by Distribution Channel, 2017–2031
12.8.1. Inpatient Nutrition
12.8.2. Outpatient Nutrition
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Cancer Type
12.11.2. By Nutrition
12.11.3. By Formula
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Oncology Nutrition Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Cancer Type, 2017–2031
13.2.1. Head and Neck Cancer
13.2.2. Colorectal Cancer
13.2.3. Hematology Cancer
13.2.4. Prostate Cancer
13.2.5. Breast Cancer
13.2.6. Gastrointestinal Cancer
13.2.7. Lung Cancer
13.2.8. Pancreatic Cancer
13.2.9. Others
13.3. Market Attractiveness, by Cancer Type
13.4. Market Value Forecast, by Nutrition, 2017–2031
13.4.1. Enteral Nutrition
13.4.2. Parenteral Nutrition
13.5. Market Attractiveness, by Nutrition
13.6. Market Value Forecast, by Formula, 2017–2031
13.6.1. Standard Formula
13.6.2. Elemental Formula
13.6.3. Specialized Formula
13.7. Market Attractiveness, by Formula
13.8. Market Value Forecast, by Distribution Channel, 2017–2031
13.8.1. Inpatient Nutrition
13.8.2. Outpatient Nutrition
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Cancer Type
13.11.2. By Nutrition
13.11.3. By Formula
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Oncology Nutrition Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Cancer Type, 2017–2031
14.2.1. Head and Neck Cancer
14.2.2. Colorectal Cancer
14.2.3. Hematology Cancer
14.2.4. Prostate Cancer
14.2.5. Breast Cancer
14.2.6. Gastrointestinal Cancer
14.2.7. Lung Cancer
14.2.8. Pancreatic Cancer
14.2.9. Others
14.3. Market Attractiveness, by Cancer Type
14.4. Market Value Forecast, by Nutrition, 2017–2031
14.4.1. Enteral Nutrition
14.4.2. Parenteral Nutrition
14.5. Market Attractiveness, by Nutrition
14.6. Market Value Forecast, by Formula, 2017–2031
14.6.1. Standard Formula
14.6.2. Elemental Formula
14.6.3. Specialized Formula
14.7. Market Attractiveness, by Formula
14.8. Market Value Forecast, by Distribution Channel, 2017–2031
14.8.1. Inpatient Nutrition
14.8.2. Outpatient Nutrition
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Cancer Type
14.11.2. By Nutrition
14.11.3. By Formula
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Oncology Nutrition Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Cancer Type, 2017–2031
15.2.1. Head and Neck Cancer
15.2.2. Colorectal Cancer
15.2.3. Hematology Cancer
15.2.4. Prostate Cancer
15.2.5. Breast Cancer
15.2.6. Gastrointestinal Cancer
15.2.7. Lung Cancer
15.2.8. Pancreatic Cancer
15.2.9. Others
15.3. Market Attractiveness, by Cancer Type
15.4. Market Value Forecast, by Nutrition, 2017–2031
15.4.1. Enteral Nutrition
15.4.2. Parenteral Nutrition
15.5. Market Attractiveness, by Nutrition
15.6. Market Value Forecast, by Formula, 2017–2031
15.6.1. Standard Formula
15.6.2. Elemental Formula
15.6.3. Specialized Formula
15.7. Market Attractiveness, by Formula
15.8. Market Value Forecast, by Distribution Channel, 2017–2031
15.8.1. Inpatient Nutrition
15.8.2. Outpatient Nutrition
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Cancer Type
15.11.2. By Nutrition
15.11.3. By Formula
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Danone S.A.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. B. Braun Melsungen AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Fresenius Kabi AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Grifols S.A.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Baxter International, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Nestle S.A.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Abbott Laboratories
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. AbbVie, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Sichuan Kelun Pharmaceutical Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview